+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Non Small-Cell Lung Cancer Market By Type, By Treatment Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 262 Pages
  • October 2022
  • Region: Global
  • Allied Market Research
  • ID: 5725358
The global non-small cell lung cancer treatment market was valued at $15,335.0 million in 2021, and is projected to reach $36,934.19 million by 2031, registering a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer (NSCLC), is a type of lungs cancer that occurs in the epithelial tissues of the lungs. NSCLC mostly occurs in people who smoke or have a history of smoking. It also occurs in people who are exposed to polluted air, such as radon, asbestos, and others. The treatment of cancer in patients requires the use of different techniques, such as immunotherapy, targeted therapy, and chemotherapy.

NSCLC can be cured, especially if action is taken before the disease spreads to other organs. Doctor may only need to do surgery if the cancer is contained to a tiny area of the lungs. Additional therapies may be necessary for a more advanced malignancy. Furthermore, rise in tobacco consumption, rising prevalence of non-small lung cancer market, early screening of the cancer, and availability of cancer drugs are expected to boost the market growth. For instance, according to National Centre for Biotechnology Information (NCBI), 85% of lung cancer diseases are non-small cell lung cancer cases.
However, high cost involved in treatment therapies coupled with threat of adverse side-effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global NSCLC treatment market is segmented by type, treatment type, distribution channel, and region. Depending on treatment type, the market is divided into chemotherapy, targeted therapy, and immunotherapy. By type, it is categorized into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others (adenosquamous carcinoma, sarcomatoid carcinoma) and by distribution channel, it is segmented into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy.

Region-wise, the market is studied across North America (the U. S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global non small cell lung cancer market analysis from 2021 to 2031 to identify the prevailing global non small cell lung cancer market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global non small cell lung cancer market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global non small cell lung cancer market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Others
  • Adenocarcinoma

By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • U. S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • Astrazeneca
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Sanofi
  • boehringer ingelheim
Frequently Asked Questions about the Global Non-Small Cell Lung Cancer Treatment Market

What is the estimated value of the Global Non-Small Cell Lung Cancer Treatment Market?

The Global Non-Small Cell Lung Cancer Treatment Market was estimated to be valued at $15335 million in 2021.

What is the growth rate of the Global Non-Small Cell Lung Cancer Treatment Market?

The growth rate of the Global Non-Small Cell Lung Cancer Treatment Market is 9.2%, with an estimated value of $36934.19 million by 2031.

What is the forecasted size of the Global Non-Small Cell Lung Cancer Treatment Market?

The Global Non-Small Cell Lung Cancer Treatment Market is estimated to be worth $36934.19 million by 2031.

Who are the key companies in the Global Non-Small Cell Lung Cancer Treatment Market?

Key companies in the Global Non-Small Cell Lung Cancer Treatment Market include F. Hoffmann, La Roche Ltd., Novartis AG, Pfizer Inc., Astrazeneca, Eli Lilly and Company, Merck & Co. Inc., Bristol, Myers Squibb Company and Celgene Corporation.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Adenocarcinoma
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Squamous Cell Carcinoma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Large Cell Carcinoma
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country

CHAPTER 5: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Chemotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Targeted Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Immunotherapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country

CHAPTER 6: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug Store and Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country

CHAPTER 7: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Treatment Type
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Treatment Type
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Treatment Type
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Treatment Type
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Treatment Type
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Treatment Type
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Treatment Type
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Treatment Type
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Treatment Type
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Treatment Type
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Treatment Type
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Treatment Type
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Treatment Type
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Treatment Type
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Treatment Type
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Treatment Type
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Treatment Type
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Treatment Type
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Treatment Type
7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Novartis AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Astrazeneca
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Bristol-Myers Squibb Company
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Celgene Corporation
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 boehringer ingelheim
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Global Non Small Cell Lung Cancer Market,' the global non small cell lung cancer market size was valued at $15.3 billion in 2021, and is estimated to reach $36.9 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer is caused when the cells present in the body grow at an uncontrolled rate, leading to the formation of a tumor. NSCLC has different stages based on its progression. STAGE IV is the final stage of the disease, which is marked by the spreading of tumors into others parts of body. The management of NSCLC in patients requires the use of different treatments, such as immunotherapy, targeted therapy, and chemotherapy. Increased use of tobacco, excessive exposure to pollution and higher number of R&D activities to develop cancer therapeutics are some of the major non small cell lung cancer market trends. Also, promising drugs in late stage of pipeline with high potential of emerging economies is further expected to provide lucrative opportunities for market expansion.

It has been found that more than 90% of non-small lung cancer is due to smoking, and tobacco use is a leading cause of non-small cell lung cancer. According to a study, men who smoke are 23 times more likely to develop this non-small cell lung cancer, while women are 13 times more susceptible to develop non-small cell lung cancer.

Not only is tobacco consumption through smoking the sole reason of developing non-small cell lungs cancer, but direct exposure to polluted air particles, such as diesel exhaust, asbestos and others may also lead to non-small lung cancer disease. However, adverse effects such as death rate related to the NSCLC impede the market growth.

The overall 5-year survival rate is 63% for those with localized NSCLC, which implies cancer has not migrated outside the lung. The 5-year survival rate for regional NSCLC is roughly 35%, meaning cancer has progressed to neighboring lymph nodes in addition to the lung. The 5-year survival rate for metastatic lung cancer, which has spread to a distant organ is 7%.

However, recent research and development in this field also ensure that more recent treatments, such as targeted medicines and immunotherapies allow people with metastatic lung cancer to live longer than ever before.

On the basis of non small cell lung cancer market analysis, the targeted therapy segment is anticipated to grow with the largest share during the forecast period. This is attributed to the identification of molecular targets of cancer cells, fewer adverse effects, and the availability of number of approved targeted therapeutics for non-small cell lung cancer. Recent advances in cellular technology have contributed to improve the understanding of tumor cells and their metabolism at molecular level, thus driving the need for targeted drug therapies for cancer treatment. On the other side, the demand for immunotherapy is projected to exhibit the fastest market growth during the forecast period due to its effectivity and expected launch of pipeline immunotherapies. For instance, a study conducted by UCLA researchers involving patients with non-small cell lung cancer (NSCLC) found that the immunotherapy drug pembrolizumab increased the average 5-year survival rate of these patients from 5.5% to 15%. Also, researchers at Johns Hopkins Kimmel Cancer Center are conducting several studies and research into novel immunotherapy, known as anti-PD1 and anti-PD L1. These therapies have the potential to increase survival and clinical rate.

By type, the adenocarcinoma segment dominated the non small cell lung cancer industry in 2021, and is anticipated to continue this trend during the forecast period. According to the NCBI, the main risk factor for any carcinoma, especially adenocarcinoma is smoking tobacco. Due to numerous carcinogens present in tobacco smoke, primary or secondary exposure increases risk proportional to the amount of exposure. In addition, adoption of unhealthy lifestyle, exposure to harmful radiation, and increasing governmental initiatives also contribute toward the growth of the market.

North America accounted for the largest non small cell lung cancer market share in 2021, and is anticipated to maintain its dominance from 2021 to 2031. The dominance is due to presence of large patient population, strong presence of key players, well-developed non small cell lung cancer industry, favorable reimbursement policies, and higher number of research and developments. Non-small lung cancer accounts for more than 85% of lung cancer in the U.S. However, Asia-Pacific is expected to witness growth at the highest CAGR during non small cell lung cancer market forecast owing to increase in number of cancer affected patients and rise in awareness related to NSCLC.

KEY FINDINGS OF THE STUDY

By treatment type, the targeted therapy segment dominated the market in 2021 and the immunotherapy segment is expected to grow at the highest CAGR during the forecast period.

By type, the adenocarcinoma segment dominated the market in 2021 and the large cell carcinoma segment is expected to grow at the highest CAGR during the forecast period.

By distribution channel, the hospital pharmacy segment held the largest non small cell lung cancer market share in 2021 and the online pharmacy segment is expected to grow at the highest CAGR during the forecast period.

By region, North America dominated of the non small cell lung cancer market size in 2021. Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Astrazeneca
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Sanofi
  • Boehringer Ingelheim

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...